PCM
EGRX

Prelude Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Prelude Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,800
Closed -$126K – 1831
2016
Q3 		$126K Buy
+1,800
New +$99.7K 0.01% 739

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's EGRX Position: Q2 2019 in Review

Prelude Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 136 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in EGRX in Q3 2014 and held it in 10 quarters. The position peaked at $259K in Q4 2016. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

  • Prelude Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Prelude Capital Management sold 136 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $7K.
  • Prelude Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
  • Prelude Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $259K in Q4 2016.
  • 180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.